Lisa Walter
Stock Analyst at RBC Capital
(2.83)
# 1,642
Out of 5,117 analysts
10
Total ratings
66.67%
Success rate
29.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $7.97 | +100.75% | 1 | Nov 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $26 → $32 | $7.97 | +301.51% | 2 | Nov 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $41 → $45 | $31.88 | +41.15% | 2 | Nov 6, 2025 | |
| EYPT EyePoint | Maintains: Outperform | $28 → $39 | $18.29 | +113.23% | 2 | Nov 6, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $569 → $587 | $507.16 | +15.74% | 2 | Oct 30, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $17 → $19 | $24.97 | -23.91% | 1 | Aug 1, 2025 |
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $7.97
Upside: +100.75%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $7.97
Upside: +301.51%
Viridian Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $41 → $45
Current: $31.88
Upside: +41.15%
EyePoint
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $18.29
Upside: +113.23%
United Therapeutics
Oct 30, 2025
Maintains: Outperform
Price Target: $569 → $587
Current: $507.16
Upside: +15.74%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Sector Perform
Price Target: $17 → $19
Current: $24.97
Upside: -23.91%